Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi. Under the terms of the agreement, and subject to customary conditions, Vicebio shareholders will receive up to a total of US$1.6 billion, […]
Next Monday (July 28) is World Hepatitis Day, which recognises the huge global impact of this disease of the liver, which causes some 1.3 million deaths a year. Most of those result from infection with the Hepatitis B virus, which is commonly transmitted from mother to child during delivery, as well as through contact with […]
One Biosciences announces €15 Million Series A financing to advance clinical single cell profiling One Biosciences, a precision oncology techbio company pioneering clinical grade single-cell tumour transcriptomic profiling, announced a €15 million Series A financing led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. […]
The patent cliff is looming and Big Pharma firms are concerned. Hungry to fill revenues holes which will soon start to open up, they are on the lookout for tasty biotechs with oven-ready assets. Last week, Merck & Co pounced – with the purchase of our client London-based Verona Pharma for a cool $10 billion. […]
Firstly, congratulations to the team at Verona Pharma on their incredible $10bn dollar deal with Merck! And to Actithera on their oversubscribed $75.5M Series A – a great achievement in the current market. Huge congratulations also go to the incomparable Clive Cookson on receiving the Lifetime Achievement Award at the Association of British Science Writers […]
